id,question,opa,opb,opc,opd,cop,choice_type,exp,subject_name,topic_name,dataset_split,llama3-8b_response,llama3-8b_answer,llama3-8b_response_parsed
a3da135a-a6a2-4e1c-8823-8ab0913f5668,"A patient presented to emergency with overdose some drug. There were increased salivation and increased bronchial secretions. On examination, blood pressure was 88/60 mmHg. RBC esterase level is 50. What should be the treatment of this person?",Neostigmine,Atropine,Flumazenil,Physostigmine,1,single,"Low esterase levels are suggestive of overdose of some drug which acts by inhibiting acetyl choline esterase like organophosphate poisoning. Inhibition of choline esterase results In increased amount of Ach at synapse, so poisoning or overdose results in cholinergic symptoms like salivation, lacrimation, urination, emesis, increased bronchial secretions, reduction in blood pressure.So treatment Of choice is Atropine. Atropine -It is highly effective in counter-acting the muscarinic symptoms, but higher doses are required to antagonize the central effects. It does not reverse peripheral muscular paralysis which is a nicotinic action. All cases of anti-ChE (carbamate or organophosphate) poisoning must be promptly given atropine2 mg i.v. repeated every 10 min till dryness of mouth or other signs of atropinization appear (upto 200 mg has been administered in a day). Continued treatment with maintenance doses may be required for 1-2 weeks. Neostigmine and physostigmine worsens the signs and symptoms as these also act by inhibiting choline esterase. Physostigmine and flumazenil are respectively used for Atropine and benzodiazepines poisoning.",Pharmacology,AIIMS 2019,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In this scenario, the patient is presenting with symptoms of cholinergic excess, including increased salivation, increased bronchial secretions, and hypotension (low blood pressure). These symptoms suggest an overdose of a cholinesterase inhibitor. The elevated RBC esterase level supports this diagnosis. Atropine is the appropriate antidote, as it is a muscarinic receptor antagonist that will help reverse the cholinergic effects and improve cardiovascular stability. Neostigmine could potentially exacerbate symptoms, Flumazenil is used to reverse benzodiazepine overdose, and Physostigmine has a narrow therapeutic window and can also cause cholinergic side effects.""
}",B,"In this scenario, the patient is presenting with symptoms of cholinergic excess, including increased salivation, increased bronchial secretions, and hypotension (low blood pressure). These symptoms suggest an overdose of a cholinesterase inhibitor. The elevated RBC esterase level supports this diagnosis. Atropine is the appropriate antidote, as it is a muscarinic receptor antagonist that will help reverse the cholinergic effects and improve cardiovascular stability. Neostigmine could potentially exacerbate symptoms, Flumazenil is used to reverse benzodiazepine overdose, and Physostigmine has a narrow therapeutic window and can also cause cholinergic side effects."
a570d3c3-865a-41b6-8e21-dccbf7feec4c,"A patient from,nqh-eastern states was diagnosed to have infection with P. falciparum malaria. What is the most appropriate drug for this patient?",Aemether plus lumefantrine,Sulfadoxine plus pyrimethamine,Chloroquine,Mefloquine,0,single,"Ans: A. Aemether plus lumefantrineRef: <a href="" Combination Therapy (ACT) should be given to all the confirmed P. falciparum cases.</li>The ACT recommended in the National Program all over India except noheastern states is aesunate (AS) daily for3 days and Sulfadoxine-pyrimethamine (SP) on Day 0.Noheastern states presently recommended ACT in national drug policy is fixed dose combination of Aemether-lumefaritrine.Hence, the clear-cut answer of this question is Aemether plus lumefantrine.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The patient has P. falciparum malaria, which is prevalent in the eastern states and other areas where resistance to chloroquine is common. The most preferred treatment for P. falciparum malaria, especially in cases where artemisinin combination therapy (ACT) is available, is an artemether-based regimen. Aemether plus lumefantrine (Coartem) is the first-line treatment recommended by the World Health Organization (WHO) for uncomplicated P. falciparum malaria in the eastern states. This combination provides effective suppression of asexual blood-stage parasites and gametocytes.""
}",A,"The patient has P. falciparum malaria, which is prevalent in the eastern states and other areas where resistance to chloroquine is common. The most preferred treatment for P. falciparum malaria, especially in cases where artemisinin combination therapy (ACT) is available, is an artemether-based regimen. Aemether plus lumefantrine (Coartem) is the first-line treatment recommended by the World Health Organization (WHO) for uncomplicated P. falciparum malaria in the eastern states. This combination provides effective suppression of asexual blood-stage parasites and gametocytes."
e7f023ea-2147-47d3-9f2a-61fb60a900be,Which of these drugs is an antidote for fibrinolytic therapy?,Epsilon aminocaproic acid,Protamine,Heparin,Streptokinase,0,single,"Answer- A. Epsilon aminocaproic acidEpsilon aminocaproic acid is an antidote for fibrinolytic therapy. Epsilon-aminocaproic qcid is a synthetic inhibitor of theplasmin-plasminogen system. It is the only potent antifibrinolylic agent, which is commercially available.""Aminocaproic acid is a lysine analog that competes for lysine binding sites on plasminogen and plasmin, blocking theinteraction of plasmin with fibrin.Fibrinolytic overdose - Epsilon Amino Caproic Acid (EACA)",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Epsilon aminocaproic acid is an antifibrinolytic agent, which is often used as an antidote for fibrinolytic therapy. Fibrinolytic therapy involves the use of drugs like Streptokinase, which work by breaking down blood clots. Epsilon aminocaproic acid counteracts this effect by inhibiting the activity of plasmin, the enzyme involved in clot breakdown. It can reverse the bleeding complications associated with fibrinolytic therapy. Therefore, option A is the correct choice as it provides an appropriate antidote for fibrinolytic therapy.""
}",A,"Epsilon aminocaproic acid is an antifibrinolytic agent, which is often used as an antidote for fibrinolytic therapy. Fibrinolytic therapy involves the use of drugs like Streptokinase, which work by breaking down blood clots. Epsilon aminocaproic acid counteracts this effect by inhibiting the activity of plasmin, the enzyme involved in clot breakdown. It can reverse the bleeding complications associated with fibrinolytic therapy. Therefore, option A is the correct choice as it provides an appropriate antidote for fibrinolytic therapy."
e881fcb0-a4f2-45ed-97cf-c53045f98e30,Absorption of which of the following drugs is increased after a fatty meal?,Amphotericin B,Griseofulvin,Ampicillin,Aspirin,1,single,"Ans: B. Griseofulvin (Ref: Goodman Gilman I2/e p1585; Katzung 13/e p632, 12/e p855,. KUT 7/e p790, 6/e p760)The oral administration of a 0.5 g dose of griseofulvin produces peak plasma concentrations of 1ug/mL in 4 hours.Improved drug absorption along with a fatty meal.Drug Absorption Reduced/Delayed by FoodDrug Absorption increased by foodAmpicillindegAspirindegAtenololdegAzithromycindegCaptoprildegCefaclorCephalexinCiprofloxacinDidanosineIndinavirdegIsoniazidaLoratidineNaficillinPenicillin G or VdegPhenobarbitaldegPhenytoindegRifampindegSucralfatedegTetracyclinedegDoxycyclinedegAtovaquonedegCarbamazepinedegChlohiazidedegCefuroximedegClofaziminedegDiazepamdegErythromycin GanciclovirdegHydrochlorothiazidedegItraconazoleaLithiumdegLovastatinMethylphenidateMetoprololdegNelfinavirNitrofurantoinPropranololdegPropoxypheneRitonavirdegSaquinavirdegSpironolactonedeg*Hydralazinedeg",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Absorption of griseofulvin is increased after a fatty meal due to its lipophilic nature. Griseofulvin is a antifungal medication that dissolves in fats and oils. The presence of a fatty meal increases the solubility of griseofulvin in fats, enhancing its gastrointestinal absorption. This is an example of how fatty meal influences the pharmacokinetics of lipophilic drugs. Options A (Amphotericin B) and C (Ampicillin) do not show significant changes in absorption with fatty meals, while D (Aspirin) is a weak acid that is not significantly affected by a fatty meal.""
}",B,"Absorption of griseofulvin is increased after a fatty meal due to its lipophilic nature. Griseofulvin is a antifungal medication that dissolves in fats and oils. The presence of a fatty meal increases the solubility of griseofulvin in fats, enhancing its gastrointestinal absorption. This is an example of how fatty meal influences the pharmacokinetics of lipophilic drugs. Options A (Amphotericin B) and C (Ampicillin) do not show significant changes in absorption with fatty meals, while D (Aspirin) is a weak acid that is not significantly affected by a fatty meal."
da27e783-4c0b-4621-bc3d-938a109d8425,Use of lithium during pregnancy increases the risk of development of which of the following malformations in the baby?,Facial defects,Cardiac defects,Neural tube defects,Urogenital defects,1,single,Lithium causes Ebstein's anomaly (malformation in tricuspid valve of hea) if given in pregnancy. Other side effects of lithium includes: Leucocytosis I Tremors (most common adverse effect) Hypothyroidism Increase Urine (polyuria) Mothers (avoided in pregnancy).,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Lithium is a mood stabilizer commonly used in the treatment of bipolar disorder. During pregnancy, the use of lithium has been associated with an increased risk of congenital anomalies, particularly those affecting the fetus's facial structure. This includes various facial defects, such as a protruding tongue, micrognathia, and epicanthus. These malformations occur due to the inhibition of the enzymes involved in the production of thyroid hormone and its analogs. As a result, the use of lithium during pregnancy requires careful consideration and monitoring to minimize potential risks to the developing fetus.""
}",A,"Lithium is a mood stabilizer commonly used in the treatment of bipolar disorder. During pregnancy, the use of lithium has been associated with an increased risk of congenital anomalies, particularly those affecting the fetus's facial structure. This includes various facial defects, such as a protruding tongue, micrognathia, and epicanthus. These malformations occur due to the inhibition of the enzymes involved in the production of thyroid hormone and its analogs. As a result, the use of lithium during pregnancy requires careful consideration and monitoring to minimize potential risks to the developing fetus."
2dd59aba-38c0-4aff-a000-1bcb640254ff,"Drug adveisement letter is a necessary component of each drug formulation and contains various information about the drug like drug dosing, frequency and half-life. Which of the following information need not be given in the drug adveisement letter?",Research papers and other aicles proving efficacy of the drug,Date of expiry of the drug,"Rare, but serious life threatening adverse-effects","Common, not so serious adverse-effects",1,single,"Ans: B. Date of expiry of the drug(Ref Goodman Gilman 12/e p1883; Manual of Experimental and Clinical Pharmacology/p 345).Date of drug expiry need not to be given in drug adveisement letter.Regulated according to The Federal Food, Drug, and Cosmetic Act.Amended (Food and Drug Administration Modernization Act of 1997).Permits use of print & television adveising for prescription drugs.Drug adveisements:Contain summary information relating to side effects, contraindications & effectiveness.Current adveising regulations:Specify that this information disclosure needs to include all risk information in a product's approved labeling or must direct consumers to healthcare professionals to obtain this information.Print adveisements:Include reprinting of risk-related sections of product's approved labeling (package inse).Television adveising:Not includes reprinting of risk-related.Note:Adveisements cannot be false or misleading or omit material facts.Must present fair balance between effectiveness & risk information.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""A drug advertisement letter, more commonly known as a 'labelling' or 'package insert', is a regulatory document that provides essential information about a drug to healthcare professionals. The primary purpose of a labelling is to provide critical information about the drug, such as its dosage, side effects, and potential interactions. Research papers and articles proving the efficacy of the drug are not a necessary component of the labelling document, as the labelling must rely solely on data approved by regulatory agencies. The focus is on providing accurate, unbiased information that helps healthcare professionals understand the drug's safe usage and potential risks.""
}",A,"A drug advertisement letter, more commonly known as a 'labelling' or 'package insert', is a regulatory document that provides essential information about a drug to healthcare professionals. The primary purpose of a labelling is to provide critical information about the drug, such as its dosage, side effects, and potential interactions. Research papers and articles proving the efficacy of the drug are not a necessary component of the labelling document, as the labelling must rely solely on data approved by regulatory agencies. The focus is on providing accurate, unbiased information that helps healthcare professionals understand the drug's safe usage and potential risks."
58ffad4a-5613-4d26-88b2-a4bb2ce2b9e6,Which of the following drugs can be stopped abruptly without any withdrawal symptoms?,Esctilaopram,Fluoxetine,Fluvoxamine,Seraline,1,single,Answer- B. FluoxetineFluoxetine has the lowest incidence of discontinuation syndrome among several antidepressants including paroxetin and venlafaxine. The longer half life of fluoxetine will avoid any withdrawal symptoms because this medication effectively tapers itself from the patient's system over a few days.,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Escitalopram is an SSRI (Selective Serotonin Reuptake Inhibitor) used in the treatment of depression and anxiety. Unlike other SSRIs, escitalopram has a relatively lower risk of withdrawal symptoms when discontinued abruptly, making it an exception compared to fluoxetine and fluvoxamine. Sertraline also exhibits withdrawal symptoms when stopped abruptly. SSRIs like fluoxetine, fluvoxamine, and sertraline have a longer half-life and more potent pharmacokinetic interactions that contribute to withdrawal symptoms upon cessation. In contrast, escitalopram has a shorter half-life and fewer pharmacokinetic interactions, reducing the risk of withdrawal symptoms.""
}",A,"Escitalopram is an SSRI (Selective Serotonin Reuptake Inhibitor) used in the treatment of depression and anxiety. Unlike other SSRIs, escitalopram has a relatively lower risk of withdrawal symptoms when discontinued abruptly, making it an exception compared to fluoxetine and fluvoxamine. Sertraline also exhibits withdrawal symptoms when stopped abruptly. SSRIs like fluoxetine, fluvoxamine, and sertraline have a longer half-life and more potent pharmacokinetic interactions that contribute to withdrawal symptoms upon cessation. In contrast, escitalopram has a shorter half-life and fewer pharmacokinetic interactions, reducing the risk of withdrawal symptoms."
3e4d2174-1e88-4652-9aed-78e71215ffe8,Vitamin D toxicity is treated with,Chloroquine,Hydroxycholoquine,Dexamethasone,Ketoconazole,2,single,"Ans. C. Dexamethasone* Dexamethasone is used in the treatment of hypercalcemia due to vitamin D toxicity. Glucocoicoid (Dexamethasone, prednisolone etc) therapy will decrease plasma calcium levels by blocking the action of vitamin D(1,25 D) which results in reduced intestinal calcium absorption and increased urinary excretion of calcium. * Other drugs like chloroquine and hydroxychloroquine are less effective in treating hypercalcemia due to vitamin D toxicity.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Vitamin D toxicity can be treated with hydrochlorothiazide and also with a drug that has a similar mechanism of action to vitamin D or its metabolites, such as activated vitamin D (calcitriol) antagonist, calcitriol itself has a narrow therapeutic window but  hydroxycholoquine (a metabolite of chloroquine) is not typically used for vitamin D toxicity and also chloroquine has a different mechanism of action, dexamethasone is a corticosteroid and ketoconazole is an antifungal. Hydroxycholoquine, the metabolite of chloroquine, is used to treat various conditions such as lupus and rheumatoid arthritis. However this is the incorrect use as it does treat hypercalcemia (which is a problem associated with Vitamin D toxicity)""
}",B,"Vitamin D toxicity can be treated with hydrochlorothiazide and also with a drug that has a similar mechanism of action to vitamin D or its metabolites, such as activated vitamin D (calcitriol) antagonist, calcitriol itself has a narrow therapeutic window but  hydroxycholoquine (a metabolite of chloroquine) is not typically used for vitamin D toxicity and also chloroquine has a different mechanism of action, dexamethasone is a corticosteroid and ketoconazole is an antifungal. Hydroxycholoquine, the metabolite of chloroquine, is used to treat various conditions such as lupus and rheumatoid arthritis. However this is the incorrect use as it does treat hypercalcemia (which is a problem associated with Vitamin D toxicity)"
6bce210a-7174-4c76-b1f0-9bc3f5c835fc,CYP50 inhibition is least by:,Pantoprazole,Rabeprazole,Lansoprazole,Omeprazole,1,single,"Ans: B. Rabeprazole(Ref: Goodman Gilman 12/e p1990; Katzung131e p1060, 12/e p1089; KDT 7/e p653).Rabeprazole:Exclusively metabolized by CYP2C19 and does not cause any inhibition of CYP450.Highest efficacy.Lansoprazole - Most potent.Rabeprazole & pantoprazole have no significant drug interactions.The FDA has issued a warning about a potentially impoant adverse interaction between clopidogrel and proton pump inhibitors.Proton pump inhibitors should be prescribed to patients taking clopidogrel only if they have an increased risk of gastrointestinal bleeding or require them for chronic gastro-esophageal reflux or peptic ulcer disease, in which case agents with minimal CYP2C19 inhibition (pantoprazole or rabeprazole) are preferred",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Among the given options, Omeprazole is known to be a non-selective CYP inhibitor. However, when compared with pantoprazole, this non-selectivity is particularly minimal in comparison to how significantly pantoprazole inhibits other types of the CYP enzymes besides CYP3A4, which leads to a significant CYP50 inhibition. While all these medications, including pantoprazole, can slightly inhibit CYP50, omeprazole is the least among them due to its unique pharmacokinetic profile.""
}",D,"Among the given options, Omeprazole is known to be a non-selective CYP inhibitor. However, when compared with pantoprazole, this non-selectivity is particularly minimal in comparison to how significantly pantoprazole inhibits other types of the CYP enzymes besides CYP3A4, which leads to a significant CYP50 inhibition. While all these medications, including pantoprazole, can slightly inhibit CYP50, omeprazole is the least among them due to its unique pharmacokinetic profile."
3b150083-1a5e-49ef-bc36-41a06b677b32,Major aim of phase 1 clinical trials is:,Safety,Efficacy,Dose,Pharmacokinetics,2,single,"Phase 1 clinical trial : It is first phase in humans. It is conducted mainly on healthy volunteers. In drugs with serious adverse effects and where alternative treatment is not available, phase 1 can be conducted on patients also. Major aim is to know the maximum tolerable dose (MTD). The aim of phase 1 trials should be marked as MTD > Dose > Pharmacokinetics > Safety",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The major aim of phase 1 clinical trials is to assess the safety of a new drug candidate in a small group of healthy volunteers or patients. During this phase, the pharmacokinetics, tolerance, and pharmacodynamics of the new drug are evaluated. Although pharmacokinetics is a component of phase 1 trials, it is not the primary aim. Therefore, safety takes precedence over efficacy, dose, and pharmacokinetics as the major aim of phase 1 clinical trials.""
}",A,"The major aim of phase 1 clinical trials is to assess the safety of a new drug candidate in a small group of healthy volunteers or patients. During this phase, the pharmacokinetics, tolerance, and pharmacodynamics of the new drug are evaluated. Although pharmacokinetics is a component of phase 1 trials, it is not the primary aim. Therefore, safety takes precedence over efficacy, dose, and pharmacokinetics as the major aim of phase 1 clinical trials."
81ba27b9-0517-444f-b592-db6a7f23c69c,Acetazolamide is given to a patient of angle closure glaucoma. It is a non-competitive inhibitor of carbonic anhydrase enzyme. Which of the following should be the effect of this drug?,Decrease in Vmax,A.Decrease in Km,Increase in both Km and Vmax,No change in Vmax,0,multi,"* Enzyme inhibition is of 3 types: Type of inhibition Km Vmax Competitive inhibition Increases No change Non competitive inhibition No change Decreases Uncompetitive inhibition Decreases Decreases * In question non competitive inhibitor is given, so answer is decrease in Vmax.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. Non-competitive inhibition decreases the Vmax, which is the maximum rate of enzyme activity. As a result, even if the substrate concentration increases, the Vmax remains unchanged. However, because the enzyme is already in a non-competitive binding state, the binding of the substrate is weaker, thus increasing the Km, which is the substrate concentration required for half-maximal enzyme activity. The enzyme's activity is directly affected and the Vmax decreases, but Km might increase. In this case we can say that it's effect is a decrease in Vmax due to Non competitive inhibition of enzyme activity.""
}",A,"Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. Non-competitive inhibition decreases the Vmax, which is the maximum rate of enzyme activity. As a result, even if the substrate concentration increases, the Vmax remains unchanged. However, because the enzyme is already in a non-competitive binding state, the binding of the substrate is weaker, thus increasing the Km, which is the substrate concentration required for half-maximal enzyme activity. The enzyme's activity is directly affected and the Vmax decreases, but Km might increase. In this case we can say that it's effect is a decrease in Vmax due to Non competitive inhibition of enzyme activity."
e7278113-c555-4128-a8df-cbd10ca7833f,"A patient is administered 200 mg of a drug. 75 mg of the drug is eliminated from the body in 90 minutes. If the drug follows first order kinetics, how much drug will remain after 6 hours?",12.5 mg,25 mg,30 mg,50 mg,2,single,Answer- C. 30 mgDrug remains in the body at the end of 4th 90 minutes (6 hours) : 48.7 -18.3 = 30.4 (Approx. 30 mg),Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The drug follows first-order kinetics, meaning its elimination rate is directly proportional to its plasma concentration. Since 75 mg of the drug is eliminated in 90 minutes, we can determine the elimination rate constant (k) using the formula: k = -ln(Nf/N0)/(t), where Nf is the final amount, N0 is the initial amount, and t is time. Rearranging, we get Nf = N0 * e^(-kt). Given t = 6 hours (360 minutes), and using the given initial and intermediate amounts, we can calculate the remaining amount. However, it's more relevant to use the information that 75 mg is eliminated every 90 minutes, or 4 times in 6 hours. After 6 hours, a fourth cycle will lead to a decrease by a factor of 1/4 (25%) for the original 75 mg eliminated in the first half of that period. Since only half of the drug is eliminated in the 6 hours, the remaining fraction would be 1 - (1/4 + 1/4 + 1/4 + 1/4), which is simply 1 - 1 = 0 (since it gets halved). Thus, for the 75 mg eliminated we're left with (0.25 + 0.25 + 0.25 + 0.25)*100 mg. The remaining drug in the body after 6 hours isn't 75 mg, but actually half of 75 mg is eliminated in 6 hours. This leaves a fraction of the original 75 mg or 75 /4. Thus 25% of that 75 mg is left after each of the 4 times it occurs in 6 hours, leaving (25*3 +12.5)*100 mg of drug. Which is equal to (75)/4*3 + 25 mg. This equals 25*(3) + 12.5 mg. Simplifying this equation gives us 75+12.5 mg. 75+ 25 = 100. However since we want the original amount we're left with which is 100 mg *12.5/100. This equals 75mg * 1/4 or 25 mg of the eliminated amount. Thus to find the remaining drug we need to find the fraction of drug in the body which is the total amount of 200 mg * (75 mg/100 mg) * (1/4) or 200 * 3 * 12.5/10000. This is 200mg * (3) * 1/8 or 50 * (3) * 1/4  which simplifies to  200 * 3/ 32. Simplifying this further we get 600/32 =  (25/16)  of the original 200 mg which equals  (25) * 2 or 50  of one of the 4 times. Thus since we want the total amount we can simply multiply  2 by the total,  2 * 50 =  100. The amount eliminated is not a total and it is half of the eliminated portion. So to obtain 1/8 of the total we multiply by 100 and then by 3 so 3/4 is eliminated and we are left with 1/4 which in 200 mg * 3/4 is  150 * 3/4  or 200/ 4 * 3 =  150 or  3/4 * 200 mg. This is equal to 150 mg. Then we need to multiply this by 12.5/100,  150 *12.5/100 = (75) * (1/4) as the original amount in milligrams which is 25 mg or  25 * 4 or 100/4. Since there are (4) half-cycles in 6 hours of the elimination we multiply this number by 4 so we get 4 * (100/4)/4 = 100 which is the total in 200 mg * 4 * 4/8 or (150-50)/2 = 100 which is the fraction for drug remaining in (200 *12.5)/8 or  200/ 8 *12.5 =  (200- (75 -25)) * (1/4 + 1/4 + 1/4 +1/4) which is (200 -50) * 1/4 * 4 since the amount of time  (t) has elapsed is 6 * (1/2) * 4 = 12 * 1/2 which simplifies to  1/2 * 12 * (75-25)/100 since this occurs in 6 hours  or 12 * 50/100.  Since time isn't linear, and time isn't the same throughout, we can multiply  the half-cycles by 200 *4 * 1/4 to the power of 2 which equals  (200 * 100/4^2)/2 or 200/16 *100 or  25 *100 /4 which is 200 *12.5/16 since  4 cycles occur in 6 hours.  4 cycles are in 6 hours * (1/4) or (25 *100/4 * (4) or  (25/4 * (4) is 4/4 = 1 cycle. 200 mg is the total in 6/2 or 3 * (100 *1/4)/2 and the cycle for the fraction is (50 *4 * 1/ 4)/2 or  (100*1/4) *2/16 is 200 * 12.5/4 * (12.5/4) which simplifies to (100 *  4/16).  In 6 hours, the amount eliminated is (200 *3 * (25 - 12.5)/  100 which equals  200 * 3 * (12.5/100) or  75 * (3) * (1/4) is 25 *3 * (1/4) + 12.5 which equals (100) * (1/4) *3 or  (25) * (100/4) which equals  (200 *12.5)/4 * (25/100) is 200/ 4 * (100/4) * (1/4).
Since we know that the half-cycles in the question are 4 * (1/2)/3 is equal to  2. The half-cycle (or half the total amount of 200 in 6 hours or 100) equals 100 * (1/3 * 4/ 4).  This makes 1/4 of 100 =  50 mg or in total 100 mg * (25/100) =  75 - 25 = 50 mg which equals 25 mg * 4.  The original question stated that 75 mg was eliminated in 6 hours or one of the half-cycles. This leaves us a remaining amount of  75 - 50  or 25 mg. Therefore the total remaining drug after six hours is 200 mg, 50% is 100 * (12.5/100).  This leaves 100 mg * (100 - 12.5)/  (100/25 *100) in  6 hours. We know there are (6 / 2/ 1/2) - (4/ 5 * 3) or (3 *  6/ (12) - 4/5 * (12/12) * 6/4 or 3 * (1/2) *  (100/4 * (6/ 6) - (3 * 12.5 * 4)/ (100 * (12.5/100)). This simplifies to (3 * 1/2 *4) * 100 * 4/4 * (3 * 12.5)/ (100 * (12.5/100)). The number of (1/2) cycles left equals 100/4 or 25 mg in 200 *  (12.5 /4)/100 * (12.5/100). This simplifies to  12.5 since 200 *100/100 equals 200. In total, after the cycles are over (i.e., 6/ 3 * ( 1/2 * 12/12) equals (1/3 *3 *3 * (100*1/4)/2 since (1/6) *  (6) equals 12/12. Then we can multiply all these by 1/4 or 0.25 so that the result is  (25 * 100/ 4)/16 *100 *100/4, which is 25 * (100/4) * (100 * 12.5/100). This equals (1/8) * (25 *2) or 6.25 * 25 which equals  (12.5 * 2 * (50/50)) is  2 * (100/ 2)/4.  Since the result is 100 mg, we get that (200 * 25/100) is the answer.  However to find the total remaining dose we multiply 200 by (1/4)^ 3 * (12.5/100). This equals  25 * 75/100.
 
The simplified explanation (using half-cycles is a bit incorrect as the formula above is complex but can result in the final solution).  A simpler way to get this answer: after the first 90 minutes, half of 200 mg will be eliminated, resulting in 100 mg. In the next half-cycle (90 minutes), half of 100 mg will be eliminated, resulting in 50 mg. In another half-cycle, half of 50 mg will be eliminated, resulting in 25 mg. Since half of 25 mg will be eliminated in the last 90 minutes, the final amount of 25 mg remaining is 25/2 = 12.5 mg. In this simplified explanation, you can multiply by 4 because it is 2 half cycles (i.e., (2 * 100 / 2 * 50 / 2 * 25 / 2 * 12.5) for the final answer of the remaining amount after 6 hours, which still equals to 12.5 * 4 or 200/ 4 * 25.  However, this result does not match the correct result. Therefore to reach the correct answer we will have to go back to our equation  (75/4) *4 since this equals 100 * 12.5/100 which is 25. Then 25 *  4 or 25 *  (25) would be  500 * (100/400) or 500/4. However, to get the remaining amount of the 25 in one of the half-cycles we would need to get 25/8 which still isn't the answer of 6 hours * (1/4) or (1/4) of the cycles of (200 * 100/100).""
 
The simplified explanation with respect to the original answer can be done with the equation 200 mg - 12.5 * (3) for (100 mg) or in the equation of 200 * (3 * (1/4) or 3*1/4). Since there are  100 mg * (1/2) remaining after one of 100 mg's half-cycles for 200 mg,  this can be multiplied to give  100 * (100/200) * (100/50 * 1/2) - 100  since the cycles can be added together to give us a final answer of (100 * (4)/8 *  ( 1/4) * ( 100 * (100/4 * 4 *3)) (1/4)/  4 or  100 * (1/4). Thus, the answer is (200 * (3)/8) or (100 * 200/200 * (4/4) * (100/100 *  1/4) *  100 /  4  or  (4 * 3 *  100 * 1/4) which simplifies to  (3/2) * (100 * 4/16 *  ( 50)).  However this doesn't give us the right  answer. We can use simpler terms, the answer can be found with the following equation:  25 * 50 * 100/ (100 * 100) * (50 * 100/ 200). The answer should be  100 *  (12.5) or  3/2. Then we get the final equation of ((100 * (4) * (12.5)) or  (100 * 3)) since the cycle of half of the dose in the equation will end at 100mg. Therefore, our original equation is  200 mg - 75 mg - 25 mg - 12.5 mg and in terms of a factor, we can multiply it by 4 for the final answer which is (75 *4) - (25 *2) or 300 - 50 which still equals  (100 * 3) * 100/100, however this equals  200 since  250 mg equals  (100 * 3) or 12 cycles of a half cycle of the remaining dose 100 mg. In other words 200 - (12.5 * 4) is (100 *3) or 200 - 50 or (100 *  2) = (200/ 4). Therefore our answer is simply (200 *  3/ 2 or  200 * 1.5 =  300/ 2 or 300/2 or  150 *  (2 * (1/2) or 150 * (1/2) or (200- 75 - 12.5) * ( 200 -  100) * (25/ 100) * (1/2) or (75 *3 * (100 / 200) * (1/4) =  100 * (1/ 4) or (3 * 25 * (4/ 4) * (100/ 200 *  (1/4) or (100 * (25/ 4)/2 or  100 *  25.",C,"The drug follows first-order kinetics, meaning its elimination rate is directly proportional to its plasma concentration. Since 75 mg of the drug is eliminated in 90 minutes, we can determine the elimination rate constant (k) using the formula: k = -ln(Nf/N0)/(t), where Nf is the final amount, N0 is the initial amount, and t is time. Rearranging, we get Nf = N0 * e^(-kt). Given t = 6 hours (360 minutes), and using the given initial and intermediate amounts, we can calculate the remaining amount. However, it's more relevant to use the information that 75 mg is eliminated every 90 minutes, or 4 times in 6 hours. After 6 hours, a fourth cycle will lead to a decrease by a factor of 1/4 (25%) for the original 75 mg eliminated in the first half of that period. Since only half of the drug is eliminated in the 6 hours, the remaining fraction would be 1 - (1/4 + 1/4 + 1/4 + 1/4), which is simply 1 - 1 = 0 (since it gets halved). Thus, for the 75 mg eliminated we're left with (0.25 + 0.25 + 0.25 + 0.25)*100 mg. The remaining drug in the body after 6 hours isn't 75 mg, but actually half of 75 mg is eliminated in 6 hours. This leaves a fraction of the original 75 mg or 75 /4. Thus 25% of that 75 mg is left after each of the 4 times it occurs in 6 hours, leaving (25*3 +12.5)*100 mg of drug. Which is equal to (75)/4*3 + 25 mg. This equals 25*(3) + 12.5 mg. Simplifying this equation gives us 75+12.5 mg. 75+ 25 = 100. However since we want the original amount we're left with which is 100 mg *12.5/100. This equals 75mg * 1/4 or 25 mg of the eliminated amount. Thus to find the remaining drug we need to find the fraction of drug in the body which is the total amount of 200 mg * (75 mg/100 mg) * (1/4) or 200 * 3 * 12.5/10000. This is 200mg * (3) * 1/8 or 50 * (3) * 1/4  which simplifies to  200 * 3/ 32. Simplifying this further we get 600/32 =  (25/16)  of the original 200 mg which equals  (25) * 2 or 50  of one of the 4 times. Thus since we want the total amount we can simply multiply  2 by the total,  2 * 50 =  100. The amount eliminated is not a total and it is half of the eliminated portion. So to obtain 1/8 of the total we multiply by 100 and then by 3 so 3/4 is eliminated and we are left with 1/4 which in 200 mg * 3/4 is  150 * 3/4  or 200/ 4 * 3 =  150 or  3/4 * 200 mg. This is equal to 150 mg. Then we need to multiply this by 12.5/100,  150 *12.5/100 = (75) * (1/4) as the original amount in milligrams which is 25 mg or  25 * 4 or 100/4. Since there are (4) half-cycles in 6 hours of the elimination we multiply this number by 4 so we get 4 * (100/4)/4 = 100 which is the total in 200 mg * 4 * 4/8 or (150-50)/2 = 100 which is the fraction for drug remaining in (200 *12.5)/8 or  200/ 8 *12.5 =  (200- (75 -25)) * (1/4 + 1/4 + 1/4 +1/4) which is (200 -50) * 1/4 * 4 since the amount of time  (t) has elapsed is 6 * (1/2) * 4 = 12 * 1/2 which simplifies to  1/2 * 12 * (75-25)/100 since this occurs in 6 hours  or 12 * 50/100.  Since time isn't linear, and time isn't the same throughout, we can multiply  the half-cycles by 200 *4 * 1/4 to the power of 2 which equals  (200 * 100/4^2)/2 or 200/16 *100 or  25 *100 /4 which is 200 *12.5/16 since  4 cycles occur in 6 hours.  4 cycles are in 6 hours * (1/4) or (25 *100/4 * (4) or  (25/4 * (4) is 4/4 = 1 cycle. 200 mg is the total in 6/2 or 3 * (100 *1/4)/2 and the cycle for the fraction is (50 *4 * 1/ 4)/2 or  (100*1/4) *2/16 is 200 * 12.5/4 * (12.5/4) which simplifies to (100 *  4/16).  In 6 hours, the amount eliminated is (200 *3 * (25 - 12.5)/  100 which equals  200 * 3 * (12.5/100) or  75 * (3) * (1/4) is 25 *3 * (1/4) + 12.5 which equals (100) * (1/4) *3 or  (25) * (100/4) which equals  (200 *12.5)/4 * (25/100) is 200/ 4 * (100/4) * (1/4)."
a5d733b4-18d3-468c-8aaa-bbcb66cbb07e,Adverse effects of salbutamol are all except,Tremors,Tachycardia,Hypoglycemia,Hypokalemia,2,multi,Salbutamol is a beta 2 agonist. Adverse effects of beta 2 agonists: Tremors Tachycardia Tolerance Hypokalemia (by enhancing potassium uptake into muscles) Hypoxia Hyperglycemia (by stimulating glycogenolysis and gluconeogenesis) Note: Tolerance occurs to only long acting beta 2 agonists .,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Salbutamol is a beta-2 adrenergic agonist used as a bronchodilator in the management of asthma and COPD. Common adverse effects include tremors (A), tachycardia (B), and hypokalemia (D) due to its mechanism of action, which involves the stimulation of beta-2 receptors, leading to increased heart rate, tremors, and potassium efflux. However, hypoglycemia (C) is not a typical or expected adverse effect of salbutamol, as it primarily affects the beta-2 receptors rather than the insulin-producing cells in the pancreas.""
}",C,"Salbutamol is a beta-2 adrenergic agonist used as a bronchodilator in the management of asthma and COPD. Common adverse effects include tremors (A), tachycardia (B), and hypokalemia (D) due to its mechanism of action, which involves the stimulation of beta-2 receptors, leading to increased heart rate, tremors, and potassium efflux. However, hypoglycemia (C) is not a typical or expected adverse effect of salbutamol, as it primarily affects the beta-2 receptors rather than the insulin-producing cells in the pancreas."
100d2a31-8f28-4500-99c9-67690fe15625,Ganglionic transmission is mediated by:,Presynaptic alpha-receptors,Postsynaptic beta-receptors,Postsynaptic dopaminergic receptors,Postsynaptic nicotinic receptors,3,single,"Ans: D .Postsynaptic nicotinic receptors(Ref: Goodman Gilman 13/e p108, 12Ie p255; Katzung 13Ie p108, 12/e p98).Ganglionic transmission is mediated by nicotinic receptors present post-synaptically.Nicotinic acetylcholine (ACh) receptor mediates neurotransmission post-synaptically at the neuromuscular junction and peripheral autonomic ganglia.In CNS, controls release of neurotransmitters from presynaptic sites.The receptor is called the nicotinic acetylcholine receptor - Due to both alkaloid nicotine & neurotransmitter ACh can stimulate the receptor.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Ganglionic transmission primarily involves the interaction between acetylcholine released from the presynaptic neuron and nicotinic receptors on the postsynaptic neuron. These nicotinic receptors are a type of ionotropic receptor that facilitates the rapid transmission of signals between neurons. The activation of these receptors leads to the opening of sodium and calcium channels, resulting in depolarization of the postsynaptic neuron. Nicotinic receptors play a crucial role in the autonomic nervous system, and their activation contributes to the transmission of signals in ganglionic synapses.""
}",D,"Ganglionic transmission primarily involves the interaction between acetylcholine released from the presynaptic neuron and nicotinic receptors on the postsynaptic neuron. These nicotinic receptors are a type of ionotropic receptor that facilitates the rapid transmission of signals between neurons. The activation of these receptors leads to the opening of sodium and calcium channels, resulting in depolarization of the postsynaptic neuron. Nicotinic receptors play a crucial role in the autonomic nervous system, and their activation contributes to the transmission of signals in ganglionic synapses."
6e09a527-f1c4-4c9b-973b-aa93392f3f75,"One of the many mechanisms of adverse events is its increased binding to secondary targets, usually proteins. With respect to the primary target, the secondary target:",Should be present in the same tissue as the primary target,Should have similar binding sites,Should have absolutely identical secondary structure,Should have a similar primary structure,1,multi,Ans. b. Should have similar binding sites (Ref: vvww'plosone'org)Secondary site compared to the primary site has the same sequence of binding site.,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""In Pharmacology, adverse events often occur due to the increased binding of a drug to secondary targets. Secondary targets are usually proteins that are not the primary site of action for the drug. For a secondary target to mediate an adverse effect, it should ideally be present in the same tissue as the primary target. This is because the drug can easily interact with and affect the secondary target if they coexist in the same tissue. Options B, C, and D are not correct because while similarities in binding sites or structure may contribute to interaction, they are not necessary for secondary targets to be present in the same tissue.""
}",A,"In Pharmacology, adverse events often occur due to the increased binding of a drug to secondary targets. Secondary targets are usually proteins that are not the primary site of action for the drug. For a secondary target to mediate an adverse effect, it should ideally be present in the same tissue as the primary target. This is because the drug can easily interact with and affect the secondary target if they coexist in the same tissue. Options B, C, and D are not correct because while similarities in binding sites or structure may contribute to interaction, they are not necessary for secondary targets to be present in the same tissue."
c1069842-8261-4a97-b1bb-5faeaacc6435,"Patient is a known case of epilepsy, taking levetiracetam 1 gm BD. He is now seizure free from 2 years but he developed agitation and anger issues interfering with day to day activities as a result of the drug intake. What should be the next best step?",Stop levetiracetam and sta on a different antiepileptic,Discontinue the drug as he is seizure free,Slowly taper the drug over next 6 months,Continue levetiracetam since a 5-year seizure free interval is needed,2,multi,"Answer- C. Slowly taper the drug over next 6 monthsStopping or switching an antiepileptic is based on seizure free period & compliance or adverse effects of the drug.Withdrawal of therapy should be gradual over 2-3 monlhs, in the question 6 months. Anti-epileptic drug therapy shouldnever he stopped abruptly. Even if new drug is to be added/replaced, the previous drug should be gradually stoppedotherwise it can lead to breakthrough seizures.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The patient in question has developed new side effects, agitation, and anger issues, despite being seizure-free for 2 years. This suggests that levetiracetam may no longer be the best option for this individual. The correct approach would be to slowly taper the drug over the next 6 months to minimize the risk of withdrawal seizure. This approach allows for a gradual reduction in the drug's effect on the brain, potentially resolving the new side effects without causing a seizure relapse. This approach is in line with the principles of medication tapering in clinical practice.""
}",C,"The patient in question has developed new side effects, agitation, and anger issues, despite being seizure-free for 2 years. This suggests that levetiracetam may no longer be the best option for this individual. The correct approach would be to slowly taper the drug over the next 6 months to minimize the risk of withdrawal seizure. This approach allows for a gradual reduction in the drug's effect on the brain, potentially resolving the new side effects without causing a seizure relapse. This approach is in line with the principles of medication tapering in clinical practice."
bb46d4ce-440a-4cea-ab6f-75ce99cdd3aa,Dapsone is used for treatment of bacterial and fungal infections as well as for immunomodulatory actions. What is mechanism of dapsone for these indication?,Inhibition of cell wall synthesis,Inhibition of ergosterol in cell membranes,Inhibition of protein synthesis,Competition with PABA in folic acid synthesis,3,multi,"Sulfonamides (including Dapsone and PAS) : Competitively inhibit folic acid synthase enzyme as these are PABA analogues. Trimethoprim, Pyrimethamine : Inhibit Dihydro folate reductase enzyme (DHFRase). Inhibition of ergosterol in cell membrane (in fungus and leishmania): Amphotericin B.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dapsone exerts its effects through competition with para-aminobenzoic acid (PABA) in folic acid synthesis. This mechanism targets the synthesis of tetrahydrofolic acid, an important precursor for DNA synthesis and repair. As a result, dapsone inhibits the growth of susceptible organisms, such as bacteria and certain fungi, and has immunomodulatory effects. This competition in folic acid synthesis is consistent with the indications for dapsone, making option D the correct choice.""
}",D,"Dapsone exerts its effects through competition with para-aminobenzoic acid (PABA) in folic acid synthesis. This mechanism targets the synthesis of tetrahydrofolic acid, an important precursor for DNA synthesis and repair. As a result, dapsone inhibits the growth of susceptible organisms, such as bacteria and certain fungi, and has immunomodulatory effects. This competition in folic acid synthesis is consistent with the indications for dapsone, making option D the correct choice."
6d426ea7-e119-4b5f-be99-1e36084c332c,All are topical hemostatic agents except?,Bone wax & patty,HemCon bandage,Quikclot,Fixclot,3,multi,"Ans. D. Fixclot Topical hemostatic agents are used when surgical hemostasis is inadequate or impractical. The majority of routine, elective operations are performed in patients with normal hemostasis and with minimal blood loss.The two main categories of topical hemostatic agents are physical agents, which promote hemostasis using a passive substrate, and biologically active agents, which enhance coagulation at the bleeding site",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Bone wax and patty are classified as topical hemostatic agents that work through a mechanical mechanism, but they are primarily used as hemostatic agents in the operating room. However, this option has wax and patty (a type of paste) and primarily isn't used topical on the surface, as it has an adhesion process in the process of being applied - bone wax is applied by dipping a sterile gauze or sponge in the wax and then applying it to the bleeding site where it is heated by the body and forms a protective barrier to prevent bleeding. The others B) HemCon bandage, C) Quikclot, and D) Fixclot are all used as a topical agent on the surface to control bleeding, thus, options A) Bone wax & patty is not used as a topical hemostatic agent.""
}",A,"Bone wax and patty are classified as topical hemostatic agents that work through a mechanical mechanism, but they are primarily used as hemostatic agents in the operating room. However, this option has wax and patty (a type of paste) and primarily isn't used topical on the surface, as it has an adhesion process in the process of being applied - bone wax is applied by dipping a sterile gauze or sponge in the wax and then applying it to the bleeding site where it is heated by the body and forms a protective barrier to prevent bleeding. The others B) HemCon bandage, C) Quikclot, and D) Fixclot are all used as a topical agent on the surface to control bleeding, thus, options A) Bone wax & patty is not used as a topical hemostatic agent."
1b18ac4d-8101-48f1-bcc9-b53391c550ab,Acetazolamide is given to a patient of angle closure glaucoma. It is a non- competitive inhibitor of carbonic anhydrase enzyme. Which of the following should be the effect of this drug?,Decrease in Vmax,Decrease in Km,Decrease in both Km and Vmax,No change in Vmax,0,multi,"Enzyme inhibition is of 3 types: Type of inhibition Km Vmax Competitive inhibition Increases No change Non competitive inhibition No change Decreases Uncompetitive inhibition Decreases Decreases In question non competitive inhibitor is given, so answer is decrease in Vmax.",Pharmacology,AIIMS 2018,validation,"{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. In non-competitive inhibition, the inhibitor binds to the enzyme but not at the active site, thereby altering the shape of the enzyme. This binding does not change the maximum velocity (Vmax) of the enzyme, but rather increases the affinity of the enzyme for its substrate, reducing the Michaelis-Menten constant (Km). Therefore, the effect of acetazolamide is a decrease in Km, allowing the enzyme to bind to the substrate more easily and increase reaction rates, but without changing the Vmax.""
}",B,"Acetazolamide is a non-competitive inhibitor of the carbonic anhydrase enzyme. In non-competitive inhibition, the inhibitor binds to the enzyme but not at the active site, thereby altering the shape of the enzyme. This binding does not change the maximum velocity (Vmax) of the enzyme, but rather increases the affinity of the enzyme for its substrate, reducing the Michaelis-Menten constant (Km). Therefore, the effect of acetazolamide is a decrease in Km, allowing the enzyme to bind to the substrate more easily and increase reaction rates, but without changing the Vmax."
59ade17d-2139-4c4b-b0b5-ec6d6cf3c073,Propranolol is drug of choice for -,Ulcerated infantile hemangioma,Lymphangioma,Pyogenic granuloma,Capillary malformation,0,single,"Ans. A. Ulcerated infantile hemangiomaRef: <a href="" hemangiomas (IHs) are the most common benign pediatric soft-tissue tumors.</li>Ulceration--the most frequent complication of IH--tends to heal poorly and is associated with pain, bleeding, infection, and scarring.Mainstay treatment modalities include propranolol (b-blocker) and coicosteroids, whose effectiveness is countered by a need for long-term medication and risk of systemic adverse effects and ulcer recurrence.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Propranolol is used as a first-line treatment for infantile hemangiomas due to its effectiveness in inducing regression. The exact mechanism is not fully understood, but it is believed to involve reduction of angiogenesis, decreased vascular permeability, and reduced expression of vascular endothelial growth factor. Ulcerated infantile hemangiomas, which can be painful and lead to complications, respond particularly well to propranolol treatment. This makes option A the correct answer, as propranolol is indeed the drug of choice for ulcerated infantile hemangiomas.""
}",A,"Propranolol is used as a first-line treatment for infantile hemangiomas due to its effectiveness in inducing regression. The exact mechanism is not fully understood, but it is believed to involve reduction of angiogenesis, decreased vascular permeability, and reduced expression of vascular endothelial growth factor. Ulcerated infantile hemangiomas, which can be painful and lead to complications, respond particularly well to propranolol treatment. This makes option A the correct answer, as propranolol is indeed the drug of choice for ulcerated infantile hemangiomas."
8b72fc76-d0bf-4cd2-b7dc-05d030560c52,All are Gp lIbilIla inhibitors except:,Prasugrel,Abciximab,Tirofiban,Eptifibatide,0,multi,"Ans: A. Prasugrel(Ref Goodman Gilman 13/e p595, 12/e p870; Katzung 13/e p595, 12Ie p612; KDT 7/e p631)Prasugrel reduce platelet aggregation by inhibiting the ADP pathway of platelets. It irreversibly blocks the ADP receptor on platelets.Targets for platelet inhibitory drugs:Inhibition of prostaglandin synthesis (aspirin).Inhibition of ADP- induced platelet aggregation (clopidogrel, prasugrel, ticlopidine).Blockade of glycoprotein Ilb/IIIa receptors on platelets (abciximab, tirofiban, and eptifibatide). Dipyridamole & cilostazol - Additional antiplatelet drugs.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""This question requires identifying drugs that are not Gp IIb/IIIa inhibitors. Gp IIb/IIIa inhibitors are a class of antiplatelet agents that work by inhibiting the glycoprotein IIb/IIIa receptor on platelet membranes, preventing platelet aggregation. Abciximab, Tirofiban, and Eptifibatide are all Gp IIb/IIIa inhibitors. However, Prasugrel is a P2Y12 receptor inhibitor, which is a different class of antiplatelet agents. In contrast to Gp IIb/IIIa inhibitors, P2Y12 receptor inhibitors work by inhibiting ADP binding to its receptor, resulting in reduced platelet aggregation. Therefore, the correct answer is option B, Abciximab.""
}",B,"This question requires identifying drugs that are not Gp IIb/IIIa inhibitors. Gp IIb/IIIa inhibitors are a class of antiplatelet agents that work by inhibiting the glycoprotein IIb/IIIa receptor on platelet membranes, preventing platelet aggregation. Abciximab, Tirofiban, and Eptifibatide are all Gp IIb/IIIa inhibitors. However, Prasugrel is a P2Y12 receptor inhibitor, which is a different class of antiplatelet agents. In contrast to Gp IIb/IIIa inhibitors, P2Y12 receptor inhibitors work by inhibiting ADP binding to its receptor, resulting in reduced platelet aggregation. Therefore, the correct answer is option B, Abciximab."
45ea4d89-40f7-42af-8f94-b4dc1e9a5466,"While assessing the efficacy of a newly developed drug in comparison to placebo, the 95% confidence interval in clinical trials is used to check for:",Efficacy of the drug,Non-efficacy of the drug,Both efficacy and non-efficacy of the drug,Either efficacy or non-efficacy of the drug,0,multi,Answer- a (efficacy of the drug),Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The 95% confidence interval (CI) in clinical trials is a statistical tool used to estimate a treatment effect, such as the difference in efficacy between a drug and a placebo. When the CI does not include zero (0), it suggests a statistically significant treatment effect, indicating the drug is efficacious. Conversely, if the CI includes zero (0), the treatment effect is considered statistically insignificant, suggesting non-efficacy. Therefore, the 95% CI is used to check for both efficacy (when the CI does not include zero) and non-efficacy (when the CI includes zero) of the drug.""
}",C,"The 95% confidence interval (CI) in clinical trials is a statistical tool used to estimate a treatment effect, such as the difference in efficacy between a drug and a placebo. When the CI does not include zero (0), it suggests a statistically significant treatment effect, indicating the drug is efficacious. Conversely, if the CI includes zero (0), the treatment effect is considered statistically insignificant, suggesting non-efficacy. Therefore, the 95% CI is used to check for both efficacy (when the CI does not include zero) and non-efficacy (when the CI includes zero) of the drug."
b57b3bed-fda6-48e7-9af4-f72d5a4687d9,Pegloticase is used in,Chronic gout,Paralytic ileus,Psoriatic ahritis,Rheumatoid ahritis,0,single,"Pegloticase - It is recombinant uricase, an enzyme which oxidises uric acid to highly soluble allantoin, that is easily excreted by kidney. Humans lack this enzyme. In this preparation, the enzyme has been coupled with methoxy polyethylene glycol (mPEG) which serves to prolong its sojourn in the body, permitting i.v. infusion of the drug to be given every 2 weeks. It is indicated only in rare cases of refractory symptomatic gout because it is immunogenic and carries high risk of infusion reactions, including anaphylaxis.",Pharmacology,AIIMS 2019,validation,"{
  ""Correct answer"": ""A"",
  ""Reasoning"": ""Pegloticase is a recombinant, mammalian cell-derived uricase enzyme used to treat chronic gout. It works by converting uric acid into allantoin, which is more soluble and can be easily excreted in the urine, thereby reducing serum urate (sUA) levels. Pegloticase is specifically indicated for the treatment of adult patients with chronic gout refractory to conventional therapy. This makes option A the correct answer. Options B, C, and D are incorrect as pegloticase is not used to treat paralytic ileus, psoriatic arthritis, or rheumatoid arthritis.""
}",A,"Pegloticase is a recombinant, mammalian cell-derived uricase enzyme used to treat chronic gout. It works by converting uric acid into allantoin, which is more soluble and can be easily excreted in the urine, thereby reducing serum urate (sUA) levels. Pegloticase is specifically indicated for the treatment of adult patients with chronic gout refractory to conventional therapy. This makes option A the correct answer. Options B, C, and D are incorrect as pegloticase is not used to treat paralytic ileus, psoriatic arthritis, or rheumatoid arthritis."
1f93c541-baaf-40f2-bf91-31be29732da2,Treatment of choice for anaphylactic shock is:,Adrenaline 0.5 mL of 1:1000 solution by intramuscular route,Adrenaline 1 mL of 1:10000 by intravenous route,Atropine 3 mg intravenously,Adenosine 12 mg intravenously,0,single,"DOC is adrenaline.Route is intramuscular > subcutaneous.Dose: 0.5 ml of 1:1000(1mg/ml solution).This dose is repeated once gain within 10 minutes.If it's still not improving; then intravenous 1:10,000 dose is given.",Pharmacology,AIIMS 2017,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The treatment of choice for anaphylactic shock is adrenaline due to its rapid onset of action and ability to dilate airways, relax smooth muscle, and increase blood pressure. A dose of 0.5 mL of 1:1000 adrenaline solution via intramuscular injection is effective in emergency situations. The 1:1000 solution has a concentration of 1 mg/mL, making 0.5 mL equivalent to 0.5 mg of adrenaline. This option is the most suitable as it provides a rapid and effective response to anaphylactic shock. Intravenous adrenaline may cause severe hypotension due to its vasodilatory effects.""
}",A,"The treatment of choice for anaphylactic shock is adrenaline due to its rapid onset of action and ability to dilate airways, relax smooth muscle, and increase blood pressure. A dose of 0.5 mL of 1:1000 adrenaline solution via intramuscular injection is effective in emergency situations. The 1:1000 solution has a concentration of 1 mg/mL, making 0.5 mL equivalent to 0.5 mg of adrenaline. This option is the most suitable as it provides a rapid and effective response to anaphylactic shock. Intravenous adrenaline may cause severe hypotension due to its vasodilatory effects."
b8621196-05ba-414e-a112-0b48be3fcd7c,Which of the following diuretic can be given in mild to moderate hypeension?,Potassium sparing diuretic,Osmotic diuretic,Thiazide diuretic,Loop diuretic,2,single,"Ans: C. Thiazide diureticThiazide diuretics :Given in mild to moderate hypeension.Low-dose thiazide diuretics used alone or in combination with other antihypeensive drugs.Safe, efficacious, inexpensive & reduce clinical events. MOA:Inhibits Na/Cl- pump in DCT a Increases sodium excretion.In long term - Acts as vasodilators.Provide additive blood pressure-lowering effects (On combination with beta blockers, ACE-I, ARBs).Drug of Choicein HypeensionConditionDrug of ChoiceHypeensionThiazidesHypeension with BPHPrazosinHypeension with diabetes mellitusACE inhibitorsHypeension with ischemic hea disease (angina)Beta-blockersHypeension with chronic kidney diseaseACE inhibitorsHypeension in pregnancyAlpha-methyldopaHypeensive emergenciesNicardipine + EsmololHypeensive emergencies in cheese reactionPhentolamineHypeensive emergencies in clonidine withdrawalPhentolamineHypeensive emergencies in aoic dissectionNitroprusside + EsmololHypeensive emergencies in pregnancyLabetalol(Ref: Harrison 19/e p1623).",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Thiazide diuretics are often used as the first line of treatment for mild to moderate hypertension due to their efficacy and tolerability. They work by inhibiting sodium reabsorption in the distal convoluted tubule, resulting in increased urine production and decreased blood volume. Thiazides are effective in lowering blood pressure and are commonly used in combination with other antihypertensive agents. Option C is the correct choice because thiazide diuretics are well-suited for treating mild to moderate hypertension.""
}",C,"Thiazide diuretics are often used as the first line of treatment for mild to moderate hypertension due to their efficacy and tolerability. They work by inhibiting sodium reabsorption in the distal convoluted tubule, resulting in increased urine production and decreased blood volume. Thiazides are effective in lowering blood pressure and are commonly used in combination with other antihypertensive agents. Option C is the correct choice because thiazide diuretics are well-suited for treating mild to moderate hypertension."
cafc0a38-bb29-4271-a180-95433a85392c,Prucalopride drug is ?,5HT4 agonist,5HT2b agonist,5HT2b antagonist,5HT2a agonist,0,single,"Ans. A. 5HT4 agonist* Prucalopride is a drug acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.* Approved for use in Europe in 2009.* Prucalopride, a first in class dihydro-benzofuran-carboxamide, is a selective, high affinity serotonin (5-HT4) receptor agonist with enterokinetic activities.* Prucalopride alters colonic motility patterns serotonin 5-HT4 receptor stimulation: it stimulates colonic mass movements, which provide the main propulsive force for defecation.* The observed effects are exeed highly selective action on 5-HT4 receptor.* Prucalopride has >150-fold higher affinity for 5-HT4 receptors than for other receptors.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Prucalopride is correct because it is a selective 5-HT4 receptor agonist. The drug is primarily used for the treatment of chronic constipation. As an agonist, prucalopride works by activating the 5-HT4 receptors, which results in increased gastrointestinal motility, leading to relief from constipation symptoms. This class of drugs belongs to the serotonin receptor agonists and is used specifically to treat this gastrointestinal condition. The correct mechanism of action of prucalopride supports making option A the correct choice.""
}",A,"Prucalopride is correct because it is a selective 5-HT4 receptor agonist. The drug is primarily used for the treatment of chronic constipation. As an agonist, prucalopride works by activating the 5-HT4 receptors, which results in increased gastrointestinal motility, leading to relief from constipation symptoms. This class of drugs belongs to the serotonin receptor agonists and is used specifically to treat this gastrointestinal condition. The correct mechanism of action of prucalopride supports making option A the correct choice."
c3b4d610-571b-4e86-be27-d41b8b2efc65,Major determinant of loading dose of a drug is,Half life,Clearance,Volume of distribution,Bioavailability,2,single,LOADING DOSE = Vd * target plasma concentration MAINTENANCE DOSE = Clearance * target plasma concentration,Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The volume of distribution is the major determinant of the loading dose of a drug. This is because it represents the total amount of drug that will eventually distribute into the body's tissues after administration. A larger volume of distribution requires a higher loading dose to achieve the desired steady-state plasma concentration. The volume of distribution influences initial drug concentration, and an accurate estimation of this factor helps in determining the initial loading dose required for effective therapy.""
}",C,"The volume of distribution is the major determinant of the loading dose of a drug. This is because it represents the total amount of drug that will eventually distribute into the body's tissues after administration. A larger volume of distribution requires a higher loading dose to achieve the desired steady-state plasma concentration. The volume of distribution influences initial drug concentration, and an accurate estimation of this factor helps in determining the initial loading dose required for effective therapy."
5891372b-60e8-4a7c-b773-48598b2712e3,All of the following are potentially serious side effects of thioamide group of antithyroid drugs except:,Hepatic dysfunction,Severe rash,Agranulocytosis,Anaphylaxis,3,multi,"Ans: D. Anaphylaxis(Ref. Goodman Gilman 12/e p1149; Katzung 13/e p671, 12/e p688)Adverse effects of anti-thyroid drugs:Most serious reaction: AgranulocytosisMC reaction: Mild, purpuric, uicarial papular rash.Less frequent complications: Pain & stiffness in joints, paresthesias, headache, skin pigmentation & loss of hair.ANCAs in -50% of patients receiving propylthiouracil.Cholestatic jaundice - More common with methimazole than propylthiouracil.Propylthiouracil-associated hepatic failure.",Pharmacology,,validation,"{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Thioamide group of antithyroid drugs, such as methimazole and propylthiouracil, can cause various side effects. Severe rash (option B) and agranulocytosis (option C) are recognized serious adverse effects of these medications. Hepatic dysfunction (option A) is also a potential side effect. Anaphylaxis (option D) is not typically associated with thioamide antithyroid drugs, as it is more commonly seen with other classes of medications such as antibiotics and NSAIDs, or in cases of iodine allergy related to radioactive iodine, which can cause thyroid inflammation. This indicates option D as the incorrect answer.""
}",D,"Thioamide group of antithyroid drugs, such as methimazole and propylthiouracil, can cause various side effects. Severe rash (option B) and agranulocytosis (option C) are recognized serious adverse effects of these medications. Hepatic dysfunction (option A) is also a potential side effect. Anaphylaxis (option D) is not typically associated with thioamide antithyroid drugs, as it is more commonly seen with other classes of medications such as antibiotics and NSAIDs, or in cases of iodine allergy related to radioactive iodine, which can cause thyroid inflammation. This indicates option D as the incorrect answer."
82356aae-5bd4-4503-acab-5f70c0db6bee,Idiosyncratic side-effects of carbamazepine are all except:,Steven-Johnson syndrome,Agranulocytosis,Rash,Blurred vision,3,multi,"Answer- D. Blurred visionDiplopia (not the blurring of vision) is a dose related side effect of carbamazepine, while others are idiosyncratic, reactions.""The most common dose-related adverse effects of carbamazepine are diplopia and ataxia. The diplopia often occursfirst and may last less than an hour during a paicular time of day",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Carbamazepine is a medication known for its potential to cause idiosyncratic side effects. Steven-Johnson syndrome, agranulocytosis, and rash are all recognized idiosyncratic reactions associated with carbamazepine. However, blurred vision is not commonly categorized as an idiosyncratic reaction for carbamazepine. Blurred vision or other ocular side effects are generally considered dose-dependent or related to the pharmacological properties of carbamazepine rather than an idiosyncratic reaction. Therefore, D is the correct answer.""
}",D,"Carbamazepine is a medication known for its potential to cause idiosyncratic side effects. Steven-Johnson syndrome, agranulocytosis, and rash are all recognized idiosyncratic reactions associated with carbamazepine. However, blurred vision is not commonly categorized as an idiosyncratic reaction for carbamazepine. Blurred vision or other ocular side effects are generally considered dose-dependent or related to the pharmacological properties of carbamazepine rather than an idiosyncratic reaction. Therefore, D is the correct answer."
f14171b9-69fe-4e7f-b004-40f2eb8d4b8c,All of these are G2 phase blockers except:,Etoposide,Topotecan,Paclitaxel,Daunorubicin,2,multi,"Ans: C. Paclitaxel(Ref: Goodman Gilman 121e p1708; Katzung 13/e p932, 12Ie p963; KDT 7/e p865)Paclitaxel:Taxane, which act by causing disruption of the cell's microtubule function by stabilizing microtubule formation.Acts on the M-phase of cell division.Binds specifically to the P-tubulin subunit of microtubules and antagonizes the disassembly of this key cvtoskeletal protein, with the result that bundles of micro-tubules and aberrant structures derived from microtubules appear in the mitotic phase of the cell cycle.Arrest in mitosis follows.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Daunorubicin is primarily a G1 phase blocker as it stabilizes the enzyme topoisomerase II-DNA complex but also causes double-strand breaks. Etoposide and Topotecan are G2 phase blockers because they inhibit topoisomerase I and II, respectively, leading to S-phase arrest. In contrast, Paclitaxel is a G2/M phase blocker by binding to microtubules, preventing their depolymerization and ultimately inducing apoptosis. Therefore, Daunorubicin is the most distinct in its mechanism of action and does not fit among the G2 phase blockers, making it the correct answer.""
}",D,"Daunorubicin is primarily a G1 phase blocker as it stabilizes the enzyme topoisomerase II-DNA complex but also causes double-strand breaks. Etoposide and Topotecan are G2 phase blockers because they inhibit topoisomerase I and II, respectively, leading to S-phase arrest. In contrast, Paclitaxel is a G2/M phase blocker by binding to microtubules, preventing their depolymerization and ultimately inducing apoptosis. Therefore, Daunorubicin is the most distinct in its mechanism of action and does not fit among the G2 phase blockers, making it the correct answer."
27a7c775-991f-4c8d-8ba3-3783c3bf92db,All of the following drugs require dose reduction in renal failure except?,Amphotericin B,Vancomycin,Gentamicin,Doxycycline,3,multi,"Those drugs which are secreted in bile do not require dose reduction in renal disease. Doxycycline is secreted in bile, so it is safe in renal failure Drugs (commonly asked) safe in renal diseases include: Safe (Cef): Cefoperazone, Ceftriaxone In The: Tigecycline R: Rifampicin E: Erythromycin N: Nafcillin A: Ampicillin L: Lincosamides (Clindamycin) Disease: Doxycycline",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""All of the listed drugs except Amphotericin B require dose reduction in renal failure. Amphotericin B primarily undergoes glomerular filtration but is not significantly excreted and also binds to lipids in tissues. Although it does bind to albumin and is excreted in a small degree through the biliary system. Despite these factors, Amphotericin B's primary concern in renal failure relates more to its effect on renal function (nephrotoxicity) rather than its need for dose reduction. Gentamicin, Vancomycin, and other drugs primarily are eliminated by the kidneys, so dose adjustment in patients with renal dysfunction is recommended.""
}",A,"All of the listed drugs except Amphotericin B require dose reduction in renal failure. Amphotericin B primarily undergoes glomerular filtration but is not significantly excreted and also binds to lipids in tissues. Although it does bind to albumin and is excreted in a small degree through the biliary system. Despite these factors, Amphotericin B's primary concern in renal failure relates more to its effect on renal function (nephrotoxicity) rather than its need for dose reduction. Gentamicin, Vancomycin, and other drugs primarily are eliminated by the kidneys, so dose adjustment in patients with renal dysfunction is recommended."
28b7a6ea-c657-4da7-81dc-88457a064655,Which of the following is not used in osteoporosis?,Milnacipran,PTH,Strontium ranelate,Denosumab,0,single,"Ans: A. Milnacipran(Ref. Goodman Gilman 12/e p1299; Katzung 13/e p761-762, 12/e p775; Harrison 19/e p2493, 18/c' p3120; Apley 9/e p /3 I-133)Milnacipran:Serotonin-norepinephrine reuptake inhibitor (SNRI).Approved for treatment of pain in fibromyalgia, not in osteoporosis.Drugs useful in OsteoporosisInhibit Bone ResorptionStimulates Bone Both actionBisphosphonates: Alendronate, risedronate & etidronateCalcium receptor agonist: CinacalcetCalcitoninSERMs: Tamoxifen, raloxifeneGallium nitrateRANKL inhibitors: DonesumabTeriparatideCalciumCalcitriolFluorideStrontium ranelate",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Milnacipran is a serotonin-norepinephrine reuptake inhibitor primarily used as an antidepressant, specifically for major depressive disorder and neuropathic pain. It is not commonly used in osteoporosis treatment. On the other hand, options B, C, and D are all established treatments for osteoporosis. PTH (parathyroid hormone) analogues are used to increase bone formation. Strontium ranelate enhances bone mineral density by promoting bone formation and reducing bone resorption. Denosumab is a monoclonal antibody that inhibits RANKL, thereby decreasing osteoclast activity and bone resorption. Therefore, milnacipran stands out as the option not used in osteoporosis treatment.""
}",A,"Milnacipran is a serotonin-norepinephrine reuptake inhibitor primarily used as an antidepressant, specifically for major depressive disorder and neuropathic pain. It is not commonly used in osteoporosis treatment. On the other hand, options B, C, and D are all established treatments for osteoporosis. PTH (parathyroid hormone) analogues are used to increase bone formation. Strontium ranelate enhances bone mineral density by promoting bone formation and reducing bone resorption. Denosumab is a monoclonal antibody that inhibits RANKL, thereby decreasing osteoclast activity and bone resorption. Therefore, milnacipran stands out as the option not used in osteoporosis treatment."
a30f9a2b-52f0-4880-980d-d56de2a88910,"Among the following propeies of dopamine, which of them is not helpful in acute shock?",Alpha-1 agonist action leading to peripheral vasoconstriction,Increase in renal perfusion due to agonist action on DI receptors,Releases noradrenaline and causes positive inotropic effect,Direct action on hea beta-1 receptors,1,single,"Ans: B. Increase in renal perfusion due to agonist action on DI receptors(Ref: Goodman Gilman 13Ie p1062, 12/e p355; KDT 71e p134, 6Ie p507)Dopamine at low concentrations (2 to 5 mug/kg per minute) primarily acts on vascular D, receptors, especially in the renal, mesenteric, and coronary beds.Increased renal perfusion caused by dopamine due to DI agonism (at low doses) doesn't improves survival in acute shock.",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Dopamine exerts a direct action on heart beta-1 receptors, but this action is not desirable in the context of acute shock. In acute shock, vasoconstriction and increased blood pressure are more desirable effects to maintain circulation and increase perfusion of vital organs. However, dopamine's direct action on beta-1 receptors may lead to increased cardiac output but also potential for increased heart rate and arrhythmias, making it less ideal in acute shock. This option (D) is not helpful in acute shock because it may cause adverse cardiovascular effects.""
}",D,"Dopamine exerts a direct action on heart beta-1 receptors, but this action is not desirable in the context of acute shock. In acute shock, vasoconstriction and increased blood pressure are more desirable effects to maintain circulation and increase perfusion of vital organs. However, dopamine's direct action on beta-1 receptors may lead to increased cardiac output but also potential for increased heart rate and arrhythmias, making it less ideal in acute shock. This option (D) is not helpful in acute shock because it may cause adverse cardiovascular effects."
5aeb3b7a-9012-4472-a233-740ba0f1dac5,Which of the following disease modifying anti-rheumatoid drugs acts by increasing extracellular adenosine?,Leflunomide,Hydroxychloroquine,Azathioprine,Methotrexate,3,single,"Answer-D. Methotrexate""Methotrexate is the DMARD of choicefor the treatment of RA and is the anchor drug for most combination therapies.At the dosages ased for lhe treatment of RA, methotrexale has been shown to stimulate adenosine release from cells, producing an anti-inflammatory effect.Methotrexate (MTX) is a folic acid analog that binds with high affinity to the active catalytic site of dihydrofolate reductase (DHFR).",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. Prolonged inhibition of this enzyme leads to an accumulation of leflunomide's active metabolite, which then increases the levels of extracellular adenosine. Elevated extracellular adenosine acts as an anti-inflammatory agent by suppressing T-lymphocyte proliferation, thus exerting its disease-modifying anti-rheumatoid effects. Therefore, among the given options, Leflunomide is the correct choice for the action of increasing extracellular adenosine.""
}",A,"Leflunomide acts by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis. Prolonged inhibition of this enzyme leads to an accumulation of leflunomide's active metabolite, which then increases the levels of extracellular adenosine. Elevated extracellular adenosine acts as an anti-inflammatory agent by suppressing T-lymphocyte proliferation, thus exerting its disease-modifying anti-rheumatoid effects. Therefore, among the given options, Leflunomide is the correct choice for the action of increasing extracellular adenosine."
fbaace6c-2dbd-458f-a1b6-8e831e7811fa,Which of these statements depicts vasomotor reversal of Dale?,Propranolol followed by adrenaline,Propranolol followed by noradrenaline,Decrease in hea rate on adrenaline administration after phentolamine has been given,Noradrenaline followed by propranolol,2,multi,"Ans: C. Decrease in hea rate on adrenaline administration after phentolamine has been given (Ref: KDT 7/e e p131, 140).This was first demonstrated by Sir HH Dale (1913) and is called vasomotor reversal of Dale.Blockade of vasoconstrictor alpha-1 (also alpha-2) receptors reduces peripheral resistance and causes pooling of blood in capacitance vessels a venous return and cardiac output are reduced a Fall in BP.Postural reflex is interfered with a marked hypotension occurs on standing a dizziness and syncope. Hypovolemia accentuates the hypotension.Decrease in hea rate on adrenaline administration after phentolamine has been given depicts vasomotor reversal of Dale.The alpha-blocker abolishes the pressor action of adrenaline (injected IV in animals), which then produces only fall in BP due to beta-2 mediated vasodilatation.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Dale's vasomotor reversal was initially observed when using adrenaline and then administering a compound that would block the effects of adrenaline. The most relevant example of this is when adrenaline is administered after the administration of a non-selective alpha-adrenergic antagonist, phentolamine. If a decrease in heart rate occurs in response to adrenaline administration after phentolamine has been given, this would indeed be the vasomotor reversal of Dale. This effect is due to the beta-adrenergic effects of adrenaline now being unopposed in the presence of phentolamine, which blocks the alpha-adrenergic effects of adrenaline""
}",C,"Dale's vasomotor reversal was initially observed when using adrenaline and then administering a compound that would block the effects of adrenaline. The most relevant example of this is when adrenaline is administered after the administration of a non-selective alpha-adrenergic antagonist, phentolamine. If a decrease in heart rate occurs in response to adrenaline administration after phentolamine has been given, this would indeed be the vasomotor reversal of Dale. This effect is due to the beta-adrenergic effects of adrenaline now being unopposed in the presence of phentolamine, which blocks the alpha-adrenergic effects of adrenaline"
5fecb77f-66cc-4650-8201-3759bda2a213,"A drug X was given continuous intravenous infusion at 1.6 mg/min. The clearance of the drug is 640 mL/min. With a half-life of 1.8 hours, what would be the steady state plasma concentration of drug?",0.002 mg/mL,0.004 trig/mL,2.88 mg/mL,3.55 mg/mL,0,single,Answer- A. 0.002 mg/mLCpss is directly propoional to the dose rate & inversely propoional to the clearance of drug.Cpss = Dose rate/clearanceDose rate= 1.6 mgiml; Clearance= 640 ml/minCpss = 1.61640 = 0.0025 mg/ml = 0.002 mg/ml,Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""The steady-state plasma concentration (Css) of a drug can be calculated using the formula: Css = (Dose / Clearance) * (1 - e^(-k*t)), where k = 0.693 / half-life. However, since the half-life can be used directly in relation to clearance, we can simplify this to Css = Dose / (Clearance / (0.693 * half-life)). Given Dose is 1.6 mg/min and Clearance is 640 mL/min, half-life is 1.8 hours or 108 minutes. Substituting these values in, Css = (1.6 mg/min) / (640 mL/min / (0.693 * 108 min))  0.002 mg/mL, making option A the correct answer.""
}",A,"The steady-state plasma concentration (Css) of a drug can be calculated using the formula: Css = (Dose / Clearance) * (1 - e^(-k*t)), where k = 0.693 / half-life. However, since the half-life can be used directly in relation to clearance, we can simplify this to Css = Dose / (Clearance / (0.693 * half-life)). Given Dose is 1.6 mg/min and Clearance is 640 mL/min, half-life is 1.8 hours or 108 minutes. Substituting these values in, Css = (1.6 mg/min) / (640 mL/min / (0.693 * 108 min))  0.002 mg/mL, making option A the correct answer."
2b110e57-8338-4189-86e2-cbea7d761c30,A diabetic patient presented with uncontrolled blood sugar level. He has history of pancreatitis and family history of urinary bladder carcinoma. He does not want to take injectable drugs. Which of the following drug can be added to control his blood sugar?,Liraglutide,Sitagliptin,Canagliflozin,Pioglitazone,2,single,"Linaglutide(-ide) is a peptide, so not given orally. It is a GLP 1(incretin) analogue and it can cause pancreatitis.Sitagliptin is a DPP 4(dipeptidyl peptidase 4) inhibitor; can cause pancreatitis.Pioglitazone(PPAR- gamma agonist) can cause urinary bladder carcinoma; so can't be given.So, canagliflozin (SGLT 2 inhibitor) can be added.",Pharmacology,AIIMS 2017,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Canagliflozin is a suitable option for this diabetic patient. It's an Sodium-glucose cotransporter-2 (SGLT2) inhibitor, which works by preventing the kidneys from reabsorbing glucose back into the bloodstream. This leads to an excretion of excess glucose through urine, thereby lowering blood sugar levels. This mechanism does not require pancreatic involvement for glucose lowering. Given the patient's pancreatitis history, this option is safer. Additionally, Canagliflozin has been reported to offer some urinary bladder cancer protection, making it an attractive choice in this scenario.""
}",C,"Canagliflozin is a suitable option for this diabetic patient. It's an Sodium-glucose cotransporter-2 (SGLT2) inhibitor, which works by preventing the kidneys from reabsorbing glucose back into the bloodstream. This leads to an excretion of excess glucose through urine, thereby lowering blood sugar levels. This mechanism does not require pancreatic involvement for glucose lowering. Given the patient's pancreatitis history, this option is safer. Additionally, Canagliflozin has been reported to offer some urinary bladder cancer protection, making it an attractive choice in this scenario."
8788091c-a8ef-4155-a7a3-8e85d643f856,"A patient presented with acute exacerbation of bronchial asthma. Salbutamol inhalation didn't improve the condition of the patient. So, intravenous coicosteroids and aminophylline were added and the condition improved. What is the mechanism of action of coicosteroids in this condition?",They cause bronchodilatation when given with xanthines,They increase bronchial responsiveness to salbutamol,They increase the action of aminophylline on adenosine receptors,They increase the mucociliary clearance,1,single,"Ans. b. They increase bronchial responsiveness to salbutamol Coicosteroids has a dual effect in acute asthma with an early facilitator effect on airway beta-2 adrenoreceptor sensitivity and a later effect on airway inflammation, which fuher emphasizes the need fir coicosteroids to he administered as early as possible during an acute asthma attack.""he molecular mechanism of action of coicosteroids involves several effects on the inflammatory process. The major effect of coicosteroids is to switch off the transcription of multiple activated genes that encode inflammatory proteins such as cytokines, chemokines, adhesion molecules, and inflammatory enzymes. This effect involves several mechanisms, including inhibition of the transcription factor NF-KB, but an impoant mechanism is recruitment of HDAC2 to the inflammatory gene complex, which reverses the histone acetylation associated with increased gene transcription. Coicosteroids also activate anti-inflammatory genes, such as mitogen-activated protein (MAP) kinase phosphatase-1, and increase the expression of IQ-receptors. Most of the metabolic and endocrine side effects of coicosteroids are also mediated through transcriptional activation.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Corticosteroids are not primarily bronchodilators and do not cause bronchodilatation. They do not increase bronchial responsiveness to salbutamol and are not known to enhance its effect. Corticosteroids, such as prednisolone, work by increasing the action of aminophylline on adenosine receptors. However, the more accurate explanation is that corticosteroids inhibit phospholipase A2, suppressing the inflammatory process, thereby increasing the effectiveness of aminophylline in treating asthma symptoms in this patient. Hence, corticosteroids indirectly contribute to the improvement of patient's condition.""
}",C,"Corticosteroids are not primarily bronchodilators and do not cause bronchodilatation. They do not increase bronchial responsiveness to salbutamol and are not known to enhance its effect. Corticosteroids, such as prednisolone, work by increasing the action of aminophylline on adenosine receptors. However, the more accurate explanation is that corticosteroids inhibit phospholipase A2, suppressing the inflammatory process, thereby increasing the effectiveness of aminophylline in treating asthma symptoms in this patient. Hence, corticosteroids indirectly contribute to the improvement of patient's condition."
d42801fb-0724-4137-b72a-3eb0d50fc9f1,Which of the following is a schedule X drug?,Thalidomide,Colistin,Ketamine,Halothane,2,single,"Ans. C. Ketamine* The following are the Schedule X drugs mentioned in the Drugs and Cosmetics Rules 1945: Amobarbital, Amphetamine, Barbital, Cyclobarbital, Dexamphetamine, Ethchlorvynol, Glutethimide, Meprobamate, Methamphetamine, Methylphenidate, Methylphenobarbital, Phencyclidine, Phenmetrazine, Secobarbital.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Thalidomide is categorized as Schedule X because it has a high potential for abuse and can cause severe harm if used illegally. Historically, thalidomide was prescribed for treating nausea and insomnia but was later withdrawn from the market due to its severe teratogenic effects, leading to birth defects. It has been granted Schedule X status under the Controlled Substances and Poisons (UK) Act to prevent its misuse and ensure safe use under medical supervision only after conducting thorough assessments and obtaining a special license.""
}",A,"Thalidomide is categorized as Schedule X because it has a high potential for abuse and can cause severe harm if used illegally. Historically, thalidomide was prescribed for treating nausea and insomnia but was later withdrawn from the market due to its severe teratogenic effects, leading to birth defects. It has been granted Schedule X status under the Controlled Substances and Poisons (UK) Act to prevent its misuse and ensure safe use under medical supervision only after conducting thorough assessments and obtaining a special license."
17ca6005-346f-4f14-b1a3-430d3667d7f0,Black deposits on conjunctiva in a patient with glaucoma are seen with the use of:,Prostaglandins,Carbonic anhydrase inhibitors,Epinephrine,Beta blocker,2,single,"Ans: C. Epinephrine(Ref: Goodman Gilman 12/e p286, 326; Katzung 13/e p161, 12/e p160; The Cornea by Smolin and Thoft's/p504)Black deposits on conjunctiva in a patient with glaucoma are seen with use of epinephrine. Latanoprost is associated with iris hyperpigmentation.Epinephrine is unstable in alkaline solution; when exposed to air or light, it turns pink from oxidation to adrenochrome and then brown from formation of polymers.",Pharmacology,,validation,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Black deposits on the conjunctiva are characteristic of deposits from latanoprost, a prostaglandin analog used in the treatment of glaucoma. Prostaglandin analogs stimulate the uveoscleral outflow, reducing intraocular pressure. However, they can cause pigment dispersion and deposition in the conjunctiva and cornea, leading to the appearance of black spots. The other options do not typically cause this specific side effect. Carbonic anhydrase inhibitors inhibit aqueous humor production but are not typically associated with black deposits. Epinephrine and beta blockers primarily affect aqueous humor outflow and are not known for this specific side effect.""
}",A,"Black deposits on the conjunctiva are characteristic of deposits from latanoprost, a prostaglandin analog used in the treatment of glaucoma. Prostaglandin analogs stimulate the uveoscleral outflow, reducing intraocular pressure. However, they can cause pigment dispersion and deposition in the conjunctiva and cornea, leading to the appearance of black spots. The other options do not typically cause this specific side effect. Carbonic anhydrase inhibitors inhibit aqueous humor production but are not typically associated with black deposits. Epinephrine and beta blockers primarily affect aqueous humor outflow and are not known for this specific side effect."
524d41bf-ef51-49b4-8662-dcaf2c2798fb,A diabetic and hypeensive patient taking several drugs presented with septicemia. Serum creatinine levels are 5.7 mg/dL. Which of the following drug should be stopped?,Insulin,Metoprolol,Linagliptin,Metformin,3,single,Serum creatinine levels are raised indicating renal failure. In renal failure and hepatic failure --> Metformin is C/I as it |ses the risk of developing lactic acidosis. Contraindicated in patients with an eGFR below 30 mL/minute/1.73 m2. eGFR should be measured annually for patients taking metformin therapy. eGFR is preferred over serum creatinine concentration to assess renal function for a person taking metformin therapy Linagliptin is a DPP-4 inhibitor. Metoprolol is a b blocker.,Pharmacology,AIIMS 2017,validation,"{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""Metformin should be stopped in a patient with septicemia and elevated serum creatinine levels (5.7 mg/dL). The kidneys play a crucial role in excreting metformin, and impaired renal function due to elevated serum creatinine levels increases the risk of metformin-induced lactic acidosis. Therefore, metformin is contraindicated in patients with serum creatinine levels above 1.5 mg/dL in men and 1.4 mg/dL in women. Continuing metformin in this patient would increase the risk of lactic acidosis, making it the incorrect choice. ""
}",D,"Metformin should be stopped in a patient with septicemia and elevated serum creatinine levels (5.7 mg/dL). The kidneys play a crucial role in excreting metformin, and impaired renal function due to elevated serum creatinine levels increases the risk of metformin-induced lactic acidosis. Therefore, metformin is contraindicated in patients with serum creatinine levels above 1.5 mg/dL in men and 1.4 mg/dL in women. Continuing metformin in this patient would increase the risk of lactic acidosis, making it the incorrect choice."
c2966f39-a3e7-464d-9048-937bf330c794,Antimalarial drug used for causal prophylaxis act at which stage of developmental cycle,Gametogony,Erythrocytic schizogony,Pre-erythrocytic schizogony,Exo-erythrocytic schizogony,2,single,Ans. C. Pre-erythrocytic schizogonyPre-erythrocytic schizogony* Occurs inside the parenchymal cells of liver.* Merozoites are liberated into blood.* Drugs acting on this stage will prevent infection of RBC and clinical attack of malaria causal prophylaxis.* Drugs are* Proguanil & Tetracycline - for falciparum.,Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The correct answer is C) Pre-erythrocytic schizogony. Antimalarial drugs used for causal prophylaxis, such as primaquine and atovaquone, target the pre-erythrocytic (liver) stage of the malaria parasite's life cycle. These drugs prevent the parasite from developing into the asexual, erythrocytic stage and thus interrupt the transmission cycle. Primaquine specifically targets the liver stages of Plasmodium vivax and Plasmodium ovale, which is essential for its causal prophylactic effect.""
}",C,"The correct answer is C) Pre-erythrocytic schizogony. Antimalarial drugs used for causal prophylaxis, such as primaquine and atovaquone, target the pre-erythrocytic (liver) stage of the malaria parasite's life cycle. These drugs prevent the parasite from developing into the asexual, erythrocytic stage and thus interrupt the transmission cycle. Primaquine specifically targets the liver stages of Plasmodium vivax and Plasmodium ovale, which is essential for its causal prophylactic effect."
407d4eec-cf0b-460c-bcdb-cf0081ec8c5d,Methacholine acts at which receptor?,M1,M2,M3,M4,1,single,"Ans: B. M2Methacholine is an M2 receptor agonist.ParameterM1M2M3Agonists (Relatively selective)Oxotremorine, MCN-343AMethacholineBethanecholAntagonists (Relatively selective)Pirenzepine, TelenzepineMethoctramine, TripitramineDarifenacin, Solifenacin",Pharmacology,,validation,"{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Methacholine is a muscarinic agonist that acts at the M2 subtype of muscarinic receptors. It primarily affects the heart, where it stimulates the M2 receptors, resulting in a decrease in heart rate. Methacholine's action on M2 receptors is responsible for its role in diagnosing and assessing the severity of obstructive airway diseases. This occurs mainly because the parasympathomimetic effects are mediated through these receptors. The other options (M1, M3, and M4) are not primarily associated with methacholine's actions, making option B the correct choice.""
}",B,"Methacholine is a muscarinic agonist that acts at the M2 subtype of muscarinic receptors. It primarily affects the heart, where it stimulates the M2 receptors, resulting in a decrease in heart rate. Methacholine's action on M2 receptors is responsible for its role in diagnosing and assessing the severity of obstructive airway diseases. This occurs mainly because the parasympathomimetic effects are mediated through these receptors. The other options (M1, M3, and M4) are not primarily associated with methacholine's actions, making option B the correct choice."
0ba46472-54a7-4bb9-9802-a0546e24cede,A bank employee felt depressed with no interest in activities came to AIIMS OPD. He was staed on Escitalopram. Which of these adverse effects cannot be explained with escitalopram?,Vivid dreaming,Anorgasmia,Sialorrhea,Nausea,2,single,"Ans. C. SialorrheaEscitalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI).Improves your energy levels and feelings of well-being and decrease nervousness.Used to treat depression and anxiety.MOA: Works by helping to restore the serotonin balance in the brain.S/E:Headache, Nausea, Ejaculation disorder, Somnolence, Insomnia, Dry mouth, Constipation, Fatigue, Libido decreased, Inability to achieve orgasm, Gas (flatulence), Toothache, Weight gain, Menstrual disorder, Neck/shoulder pain, Runny nose & Flu-like syndrome.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and other mood disorders. Common adverse effects of SSRIs include nausea, vivid dreaming, and anorgasmia. Sialorrhea, excessive salivation, is not a typical side effect of SSRIs like escitalopram. SSRIs primarily affect the brain's neurotransmitters, such as serotonin, rather than saliva production. Therefore, sialorrhea cannot be explained as a direct adverse effect of escitalopram, making option C the correct answer.""
}",C,"Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and other mood disorders. Common adverse effects of SSRIs include nausea, vivid dreaming, and anorgasmia. Sialorrhea, excessive salivation, is not a typical side effect of SSRIs like escitalopram. SSRIs primarily affect the brain's neurotransmitters, such as serotonin, rather than saliva production. Therefore, sialorrhea cannot be explained as a direct adverse effect of escitalopram, making option C the correct answer."
fc3d5863-8850-4136-8bf9-8f7bb80ca2cb,Which of the following is not true for rifabutin as compared to rifampicin?,Rifabutin has the longer half-life than rifampicin,Rifabutin has lesser incidence of drug-interactions,Rifabutin is more efficacious against MAC as compared to rifampicin,Rifabutin is more efficacious for pulmonary TB as compared to rifampicin,3,multi,"Ans: D. Rifabutin is more efficacious for pulmonary TB as compared to rifampicin(Ref Goodman Gilman 12/e p1550, 1552, 1554, 1568; Katzung 12/e p845)Rifabutin:Stronger activity against Mycobacterium avium complex (compared to rifampicin).Ineffective against Mycobacterium tuberculosis. RifabutinRifampicin (Rifampin)RifapentineProtein binding 718597Oral 2068deg-tmax (hours)2.5-4.01.5-2.05.0-6.0degHalf-life (hours)32-67deg2-5deg14-18Intracellular/extracellular9524-60degAutoinduction40%deg38%20%CYP3A inductionWeakPronouncedModerateCYP3A substrateYesdegNoNo",Pharmacology,,validation,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Rifabutin is generally used as an alternative to rifampicin in cases of drug interactions, especially when concomitant use with antiretroviral agents and protease inhibitors is necessary, due to its lower propensity for inducing the cytochrome P450 liver enzyme. However, in terms of efficacy for pulmonary tuberculosis (TB), rifampicin remains a preferred choice and the primary rifampicin derivative used in this context. While rifabutin has shown activity against Mycobacterium avium complex (MAC), its advantage over rifampicin specifically for pulmonary TB treatment is not established. Thus, option D is not true for rifabutin compared to rifampicin.""
}",D,"Rifabutin is generally used as an alternative to rifampicin in cases of drug interactions, especially when concomitant use with antiretroviral agents and protease inhibitors is necessary, due to its lower propensity for inducing the cytochrome P450 liver enzyme. However, in terms of efficacy for pulmonary tuberculosis (TB), rifampicin remains a preferred choice and the primary rifampicin derivative used in this context. While rifabutin has shown activity against Mycobacterium avium complex (MAC), its advantage over rifampicin specifically for pulmonary TB treatment is not established. Thus, option D is not true for rifabutin compared to rifampicin."
4127528f-2cc3-44bc-b07e-446577f5018c,What is the dose of adrenaline in anaphylactic shock?,0.5 ml in 1:1000,0.5 ml in 1:10000,1 ml in 1:1000,1.5 ml in 1:1000,0,single,"Ans. A. 0.5 ml in 1:1000Severe hypersensitivity reactions, anaphylactic shockIM Injection:* Adults: The usual dose is 500 micrograms (0.5ml of adrenaline 1/1000). If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function.* Half doses of adrenaline may be safer for patients who are taking amitriptyline, imipramine or a beta blocker.Paediatric population:* The following doses of adrenaline 1/1,000 are recommended:AgeDoseOver 12 years0.5 mg IM (0.5ml 1:1000 solution)6 - 12 years0.3 mg IM (0.3ml 1:1000 solution)6 months - 6 years0.15 mg IM (0.15ml 1:1000 solution)Under 6 months0.01mg/kg IM (0.01ml/kg 1:1000 solution)* If necessary, these doses may be repeated at 5-15 -minute intervals according to blood pressure, pulse and respiratory function.",Pharmacology,,validation,"{
  ""Correct answer"": ""A) 0.5 ml in 1:1000"",
  ""Reasoning"": ""The correct dose of adrenaline in anaphylactic shock is 0.5 ml of 1 in 1000 solution, which is equivalent to 0.5 mg of adrenaline. This dose is administered intramuscularly to help alleviate symptoms such as bronchospasm, hypotension, and cardiac arrest. This is a standard first-line treatment for anaphylaxis in many clinical guidelines, including those from the American Heart Association and the European Resuscitation Council.""
}",A,"The correct dose of adrenaline in anaphylactic shock is 0.5 ml of 1 in 1000 solution, which is equivalent to 0.5 mg of adrenaline. This dose is administered intramuscularly to help alleviate symptoms such as bronchospasm, hypotension, and cardiac arrest. This is a standard first-line treatment for anaphylaxis in many clinical guidelines, including those from the American Heart Association and the European Resuscitation Council."
1f6b3a83-ed5e-4d0e-90b3-f740ff95c763,All are used for postpaum hemorrhage except -,Misoprostol,Dinoprostone,Prostaglandin F2 alpha,Oxytocin,1,multi,"Ans. B. DinoprostonePostpaum hemorrhage, the loss of more than 500 mL of blood after delivery, occurs in up to 18 percent of bihs and is the most common maternal morbidity in developed countries. Dinoprostone:Naturally occurring prostaglandin E2 (PGE2). It has impoant effects in labour.It also stimulates osteoblasts to release factors which stimulates bone resorption by osteoclasts.As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour. Indication:For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed aboion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period.In the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).Other indications include improving the cervical inducibility (cervical ""ripening"") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpaum hemorrhage.",Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Prostaglandin F2-alpha is primarily used for uterine relaxation in situations like uterine inversion or to induce uterine atony, but it is not a preferred medication for treating postpartum hemorrhage (PPH) due to its potential to exacerbate bleeding. Misoprostol (A), Dinoprostone (B), and Oxytocin (D) are all effective options for PPH treatment due to their ability to induce uterine contraction. Prostaglandin F2-alpha's effect of causing uterine contraction is short-lived and may not effectively control severe bleeding, making option C the correct answer.""
}",C,"Prostaglandin F2-alpha is primarily used for uterine relaxation in situations like uterine inversion or to induce uterine atony, but it is not a preferred medication for treating postpartum hemorrhage (PPH) due to its potential to exacerbate bleeding. Misoprostol (A), Dinoprostone (B), and Oxytocin (D) are all effective options for PPH treatment due to their ability to induce uterine contraction. Prostaglandin F2-alpha's effect of causing uterine contraction is short-lived and may not effectively control severe bleeding, making option C the correct answer."
416729b9-8f0b-45d1-aa27-6674dacb9975,"At low infusion rates of 3-5 mcg/kg/min, what action is produced by dopamine?",Vasoconstriction,Increased renal blood flow,Increased cardiac contractility,Decreased blood pressure,1,single,"Ans: B. Increased renal blood flow(Ref: Goodman Gilman 12/e p355; KDT 7/e p134. 6/e p507)Action of dopamine:At low concentrations (2 to 5 mcg/kg per minute):Primarily acts on vascular D1 receptors.Mainly renal, mesenteric & coronary beds.By activating adenylyl cyclase a raising intracellular cyclic AMP concentrations.D1 receptor stimulation a Vasodilation.Increases in glomerular filtration rate, renal blood flow & Nat+ K+ - ATPase pump.",Pharmacology,,validation,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Dopamine at low infusion rates (3-5 mcg/kg/min) primarily stimulates dopamine receptors, leading to vasodilation in the renal and mesenteric blood vessels. This action enhances renal blood flow and promotes natriuresis, which contributes to the lowering of blood pressure. The increased renal blood flow is a direct result of dopamine's action on dopaminergic receptors, making option B the correct answer. Options A, C, and D are incorrect because vasoconstriction and increased cardiac contractility are seen at higher doses of dopamine (5-15 mcg/kg/min), while decreased blood pressure is more of a secondary effect of increased renal blood flow.""
}",B,"Dopamine at low infusion rates (3-5 mcg/kg/min) primarily stimulates dopamine receptors, leading to vasodilation in the renal and mesenteric blood vessels. This action enhances renal blood flow and promotes natriuresis, which contributes to the lowering of blood pressure. The increased renal blood flow is a direct result of dopamine's action on dopaminergic receptors, making option B the correct answer. Options A, C, and D are incorrect because vasoconstriction and increased cardiac contractility are seen at higher doses of dopamine (5-15 mcg/kg/min), while decreased blood pressure is more of a secondary effect of increased renal blood flow."
07c14e46-ad2b-4fde-8652-bd47b36e69ab,Vasopressin antagonist acts on which pa of the nephron?,Proximal convoluted tubule,Distal convoluted tubule,Coical collecting tubule,Medullary collecting duct,3,single,Answer- D (Medullary collecting duct)'The mechanism by which vasopressin exes its anti-diuretic effect is activated by V2 receptors and involves the inseion of aquaporin-2 into the apical (luminal) membranes at the principle cells of the collecting duct.',Pharmacology,,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Vasopressin antagonists, also known as V2 receptor antagonists, work by blocking the action of vasopressin (ADH or antidiuretic hormone) in the kidneys. Vasopressin primarily acts on the cortical collecting tubule (CCT) to increase water reabsorption. By antagonizing vasopressin, these drugs decrease water reabsorption in the CCT, leading to increased urine production and reduced water reabsorption in the kidney. This mechanism allows vasopressin antagonists to play a crucial role in treating conditions such as hyponatremia and hyponatremic syndrome of heart failure.""
}",C,"Vasopressin antagonists, also known as V2 receptor antagonists, work by blocking the action of vasopressin (ADH or antidiuretic hormone) in the kidneys. Vasopressin primarily acts on the cortical collecting tubule (CCT) to increase water reabsorption. By antagonizing vasopressin, these drugs decrease water reabsorption in the CCT, leading to increased urine production and reduced water reabsorption in the kidney. This mechanism allows vasopressin antagonists to play a crucial role in treating conditions such as hyponatremia and hyponatremic syndrome of heart failure."
604ef1a2-7595-4718-9f8c-12292063e19f,Which of the following anti-tubercular drug can cause ophthalmological toxicity?,Isoniazid,Rifampicin,Ethambutol,Pyrazinamide,2,single,"Ethambutol side effect: causes Red Green color blindness (Ophthalmological toxicity) Isoniazid side effects: Neurotoxicity, Hepatotoxicity. Pyrazinamide side effects: Hyperuricemia (gouty ahritis). Rifampicin side effects: Hepatotoxicity, orange red urine and tears etc.",Pharmacology,AIIMS 2018,validation,"{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Ethambutol is an anti-tubercular drug that can cause ophthalmological toxicity, specifically optic neuritis leading to visual disturbances or even blindness. This toxicity is dose-dependent and reversible once the drug is discontinued. In contrast, Isoniazid causes peripheral neuropathy as its major toxic effect, Rifampicin causes liver toxicity, and Pyrazinamide is associated with hepatotoxicity. Therefore, among the given options, Ethambutol is the correct choice for causing ophthalmological toxicity.""
}",C,"Ethambutol is an anti-tubercular drug that can cause ophthalmological toxicity, specifically optic neuritis leading to visual disturbances or even blindness. This toxicity is dose-dependent and reversible once the drug is discontinued. In contrast, Isoniazid causes peripheral neuropathy as its major toxic effect, Rifampicin causes liver toxicity, and Pyrazinamide is associated with hepatotoxicity. Therefore, among the given options, Ethambutol is the correct choice for causing ophthalmological toxicity."
